IV PCA Fentanyl+nefopam+Ramosetron — Competitive Intelligence Brief

IV PCA Fentanyl+nefopam+Ramosetron (IV PCA Fentanyl+nefopam+Ramosetron) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Opioid analgesic combination with antiemetic and adjuvant analgesic. Area: Pain Management / Anesthesia.

phase 3 Opioid analgesic combination with antiemetic and adjuvant analgesic Mu-opioid receptor (fentanyl); 5-HT3 receptor (ramosetron); monoamine transporters and NMDA receptor (nefopam) Pain Management / Anesthesia Small molecule

Target snapshot

IV PCA Fentanyl+nefopam+Ramosetron (IV PCA Fentanyl+nefopam+Ramosetron) — Keimyung University Dongsan Medical Center. This IV patient-controlled analgesia (PCA) combination provides opioid analgesia via fentanyl, reduces postoperative nausea and vomiting via ramosetron (5-HT3 antagonist), and enhances analgesia while reducing opioid requirements via nefopam (non-opioid analgesic).

Comparator set

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
IV PCA Fentanyl+nefopam+Ramosetron TARGET	IV PCA Fentanyl+nefopam+Ramosetron	Keimyung University Dongsan Medical Center	phase 3	Opioid analgesic combination with antiemetic and adjuvant analgesic	Mu-opioid receptor (fentanyl); 5-HT3 receptor (ramosetron); monoamine transporters and NMDA receptor (nefopam)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Opioid analgesic combination with antiemetic and adjuvant analgesic class)

1. Keimyung University Dongsan Medical Center · 1 drug in this class